Tendel therapies, INC. (75N93023C00030) title: TFH-targeting genetic adjuvants to promote durable anti-influenza stem antibodies in older adults.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93023C00030
- Awardee
-
Tendel Therapies Inc. UEI JA9BDUH73852
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,980
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20231 · Posted Jul 20, 2022
- Contract value 100% obligated
- $599,980.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 10 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Kensington, CA, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program, which aims to stimulate innovation and support small businesses in addressing federal research needs. Tendel Therapies is a biotechnology company focused on developing memory-promoting vaccines, and has received prior SBIR grants from NIH to support its research on innovative vaccine technologies, including for HIV, SARS-CoV-2, and cytomegalovirus.
Quick answers
Who was awarded contract 75N93023C00030?
75N93023C00030 was awarded to Tendel Therapies Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2023.
How much is contract 75N93023C00030 worth?
The government has obligated $599,980 on 75N93023C00030.
Was contract 75N93023C00030 competed?
The extent of competition for 75N93023C00030 was full and open competition after exclusion of sources. The government received 10 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award